Brewerton T D, Murphy D L, Mueller E A, Jimerson D C
Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, Md.
Clin Pharmacol Ther. 1988 Jun;43(6):605-9. doi: 10.1038/clpt.1988.83.
In a study of serotonin (5-HT) function in patients with eating disorders and healthy control subjects, severe headaches with features of common migraine occurred unexpectedly in 28 of 52 subjects (54%) 8 to 12 hours after receiving a single oral dose of the 5-HT receptor agonist m-chlorophenylpiperazine (m-CPP), 0.5 mg/kg. None of the same subjects developed similar late-occurring headaches after placebo or the 5-HT precursor, L-tryptophan, 100 mg/kg given intravenously. The frequency of these migrainelike headaches was not significantly different between patients with bulimia or anorexia nervosa and control subjects, but incidence of headaches was significantly greater in subjects with a personal or family history of migraine, with almost all predisposed individuals (18 of 20, 90%) developing severe symptoms. Headache ratings were also significantly correlated (rho = 0.70; p less than 0.0001) with peak concentrations of m-CPP in plasma. These observations indicate that m-CPP may provide a novel probe for studies of the pathophysiology of migraine headaches.
在一项针对饮食失调患者和健康对照者血清素(5-羟色胺,5-HT)功能的研究中,52名受试者中有28名(54%)在单次口服0.5毫克/千克5-HT受体激动剂间氯苯哌嗪(m-CPP)8至12小时后意外出现具有普通偏头痛特征的严重头痛。同一批受试者在服用安慰剂或静脉注射100毫克/千克5-HT前体L-色氨酸后均未出现类似的迟发性头痛。贪食症或神经性厌食症患者与对照者之间这些类偏头痛性头痛的发生率无显著差异,但有偏头痛个人史或家族史的受试者头痛发生率显著更高,几乎所有易感个体(20名中的18名,90%)都出现了严重症状。头痛评分也与血浆中m-CPP的峰值浓度显著相关(相关系数rho = 0.70;p < 0.0001)。这些观察结果表明,m-CPP可能为偏头痛头痛的病理生理学研究提供一种新的探针。